Replies to post #312 on Equity Field Notes from temporal sources

[DanWebzster]

SRRK is a 5/18 IPO focusing on localized protein growth factors.

Other biotech firms focusing on protein growth factors do so in a systemic way that does not control side effects well.

The lead program is a selective inhibitor of Myostatin activation aimed at reversing/preventing spinal muscle atrophy.

Cash runway extends into 2020 but dilution is likely in 2019.